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Colon Cancer Prognosis Prediction by Gene
Expression Profiling
Alain Barrier, Sandrine Dudoit, and et al.

Abstract

Aims. This study assessed the possibility to build a prognosis predictor, based
on microarray gene expression measures, in stage II and III colon cancer patients.
Materials and Methods. Tumour (T) and non-neoplastic mucosa (NM) mRNA
samples from 18 patients (9 with a recurrence, 9 with no recurrence) were profiled
using the Affymetrix HGU133A GeneChip. The k-nearest neighbour method was
used for prognosis prediction using T and NM gene expression measures. Six-fold
cross-validation was applied to select the number of neighbours and the number of
informative genes to include in the predictors. Based on this information, one Tbased and one NM-based predictor were proposed and their accuracies estimated
by double cross-validation. Results. In 6-fold cross-validation, the lowest numbers of informative genes giving the lowest numbers of false predictions (2 out of
18) were 30 and 70 with the T and NM gene expression measures, respectively.
A 30-gene T-based predictor and a 70-gene NM-based predictor were then built,
with estimated accuracies of 78 and 83%, respectively. Conclusion. This study
suggests that one can build an accurate prognosis predictor for stage II and III
colon cancer patients, based on gene expression measures, and one can use either
tumour or non-neoplastic mucosa for this purpose.

Introduction

Postoperative treatment of stages II and III colon cancer patients remains a highly
debated field. For stage II patients, the question of whether adjuvant chemotherapy should be
given or not is still unanswered. A benefit of adjuvant chemotherapy is suggested by most
meta-analyses but it has never been proved with statistical significance (Benson et al., 2004).
The reason is probably the lack of power of the studies; if existing, the benefits of adjuvant
chemotherapy are probably minor and thus, a study would need to enroll thousands of patients
to establish statistical significance. However, if such a study would show a benefit of adjuvant
chemotherapy in stage II patients, it may not be logical to conclude that this treatment should
be given to all patients, given that 75% are cured by surgery alone (IMPACT B2, 1999) .
The problem for stage III patients is somewhat different. The usefulness of adjuvant
chemotherapy has been clearly demonstrated more than 10 years ago (Moertel et al., 1990),
but the “standard” treatment, consisting of a 6-month fluorouracil (FU)-based therapy, has
been recently questioned (Andre et al., 2004). In the study of Andre et al. (Andre et al., 2004),
adding oxaliplatin to the “standard” therapy was shown to improve the three-year disease-free
survival from 73 to 79%. However, even if this improvement in survival rates is confirmed
based on five-year follow-up, it may not be logical to conclude that the “new standard”
adjuvant chemotherapy should include oxaliplatin, given its neurotoxicity (Cersosimo, 2005) .
This would lead to administering to all patients oxaliplatin that would be useful for only a
few.
In fact, the situation is quite similar for both disease stages and includes a cost-benefit
problem. Compared to the “standard” treatment (observation in stage II patients, FU-based
therapy in stage III patients), a “more aggressive” treatment (adjuvant chemotherapy in stage
II patients, oxaliplatin in stage III patients) probably benefits only a minority of patients,
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while it has no advantages or is potentially harmful for the vast majority. The situation would
be radically different if new and accurate prognosis factors could be identified. Being able to
isolate a sub-group of patients with a high risk or recurrence would permit more rational
designs of clinical studies assessing “standard” versus “more aggressive” treatment: instead of
including all patients of a given group, these studies could only include patients with a high
risk of recurrence, thus more likely to benefit from “more aggressive” treatment. Such an
approach would increase power to demonstrate a statistical significance between treatments
and would address the cost-benefit problem.
Microarray gene expression profiling has been reported to accurately predict the prognosis of
several malignant tumors (breast carcinomas (Van de Vijver et al., 2002; Van’t Veer et al.,
2002), lung carcinomas (Bhattacharjee et al., 2001; Beer et al., 2002), lymphomas
(Rosenwald et al., 2002; Shipp et al., 2002). Thus, by analogy with these tumors, it may be
postulated that gene expression profiling represents a valuable tool in predicting the prognosis
of stage II and III colon cancer patients and thereby in identifying a subgroup of patients at
high risk of recurrence. Microarray gene expression studies in colorectal cancer have so far
shown the possibility to distinguish between normal and tumor tissue samples, between
different stages of disease, and between different tumor locations (left-sided versus rightsided) (Alon et al., 1999; Backert et al., 1999; Hedge et al., 2001; Kitahara et al., 2001;
Notterman et al., 2001; Agrawal et al., 2002; Birkenkamp-Demtroder et al., 2002; Iacopetta
B, 2002; Lin et al., 2002; Zou et al., 2002; Fredericksen et al., 2003; ; Tureci et al., 2003;
Williams et al., 2003; Bertucci et al., 2004). The issue of prognosis was only recently
addressed, with promising results (Bertucci et al., 2004; Wang et al., 2004).
The present study aimed to assess the possibility to build a prognosis predictor for
both stage II and III colon cancer patients, based on microarray gene expression measures. In
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contrast to the two aformentioned studies, non-neoplastic mucosa, as well as tumor, gene
expression profiles were considered.
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Materials and Methods

Patients and samples

Eighteen patients operated on for a colonic adenocarcinoma in the Department of Digestive
Surgery of the Hospital Tenon between 1995 and 1998 were included in this study. There
were 8 women and 10 men, with a mean age of 71 years (extremes: 39-87). None of these 18
patients had distant metastasis at the time of surgery. Ten patients had no lymph node
metastasis (stage II) and did not receive any adjuvant chemotherapy. The other 8 patients had
lymph node metastasis (stage III) and received a 6-month FU-based adjuvant chemotherapy.
Patients were evaluated at 3-month intervals for the first postoperative year and at 6-month
intervals thereafter. Metastatic reccurrences were identified by clinical examination,
completed by chest X-ray and liver ultrasound (or CT scan). Nine of the 18 patients
developped a distant metastasis in the follow-up (5 stage II patients and 4 stage III patients),
while the other 9 patients remained disease-free for at least 60 months.
For each patient, tumor and adjacent non-neoplastic colon tissue samples were collected at the
time of surgery, with patients’ informed consent, and were stored in liquid nitrogen within 0.5
hour after the resection. Non-neoplastic tissue samples were collected at a distance greater
than 5 cm from the gross tumor limit with a careful dissection of the mucosa from the deeper
layers. Samples were reviewed by a pathologist to check the absence of tumor cells in nonneoplastic mucosa samples and the presence of at least 80% tumor cells in tumor samples.

Total RNA was extracted from the 36 samples (18 tumor and 18 non-neoplastic mucosa
samples) using Trizol reagent. Targets were hybridized to Affymetrix HGU133A GeneChips,
containing a total of 22,283 probe-sets (Affymetrix, Santa Clara, CA), as described in the
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Affymetrix GeneChip Expression Analysis Manual (Affymetrix, Wooburn Green, UK).
Briefly, 5 µg (100 ng/µl) of total RNA was used to synthesize double-stranded cDNA with
SuperScript II reverse transcriptase (Invitrogen, Cergy Pontoise, France) and a T7-(dT)24
primer (Proligo Biochemie GmbH, Hamburg, Germany). Then, biotinylated cRNA was
synthesized from the double-stranded cDNA using the RNA Transcript Labeling kit (Enzo
Life Sciences, Farmingdale, NY) and was purified and fragmented. The fragmented cRNA
was hybridized to the oligonucleotide microarrays, which were washed and stained with
streptavidin-phycoerythrin. Scanning was performed with a GeneArray Scanner Update
(Affymetrix, Wooburn Green, UK).

Statistical methods

Pre-processing
Starting from the 36 CEL files, gene expression measures were computed using the Robust
Multichip Average (RMA) method described in Irizarry et al. (Irizarry et al., 2003) and
implemented in the Bioconductor R package affy. This method includes the following
successive steps : 1) Backgroung correction; 2) Probe-level quantile normalization; 3)
Calculation of expression measures using median polish.
Two genes x patients matrices of expression measures were constituted including,
respectively, for each patient the gene expression measures in tumor samples and the gene
expression measures in non-neoplastic mucosa samples. In the remainder of the article, we
refer to the resulting two datasets as Tumor (T) and Non-neoplastic mucosa (NM),
respectively.

Prognosis prediction
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The prognosis prediction method consists of the following two steps.
a) Selection of informative genes. Genes that are differentially expressed between patients
who experienced a tumour relapse and patients who remained disease-free are identified
based on two-sample t-statistics with equal variance. The m genes with the largest absolute tstatistics are retained to build a prognosis predictor.
b) Prognosis prediction. The k-nearest neighbor method, based on the Euclidean distance
between the expression profiles for the m informative genes of step a), is applied to predict
prognosis. Specifically, the prognosis of a given patient is predicted as the most common
prognosis among its k nearest neighbors, i.e., the k patients with the closest expression
profiles.

Selection of prognosis predictor parameters
For each dataset (T and NM), 6-fold cross-validation was used to select the two
prognosis predictor parameters, namely the number of informative genes m and the number of
nearest neighbors k. A total of 150 prognosis predictors were considered, corresponding to the
following parameter values: k = 1, 3, and 5, and m = 5, 10, …, 250. The performance of a
given prognosis predictor, indexed by the pair (m,k), was assessed as follows. The 18 samples
were divided into 6 sets of 3 samples. Each of these 6 sets was used in turn as the validation
set; the prognosis predictor was built using the training set formed by the remaining 15
samples and used to assign a prognosis (recurrence or no recurrence) to the 3 validation
samples; the predicted prognoses were then compared to the actual recurrence status; the
numbers of false predictions (discordance between the predicted and actual evolutions) and
true predictions were recorded for each of the 18 samples. Thus, for each of the 150 prognosis
predictors, i.e., each (m,k) pair, a prediction error rate (out of 18) was obtained.
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Proposition of a prognosis predictor
For each dataset (T and NM), because of ties in the error rates in 6-fold crossvalidation, the number of informative genes of the proposed predictor was set to be the lowest
number of informative genes, giving the lowest number of false predictions. Selection of
informative genes was based on all 18 samples.

Estimation of the generalization error of the prognosis predictor
A double or nested cross-validation scheme was used to assess the performance of the
proposed T and NM prognosis predictors. For the “outer level” of cross-validation, the 18
samples were divided into 3 sets of 6 samples (3-fold cross-validation). Each of these 3 sets
was used in turn as the test set, the other 2 sets (12 patients) being used as the learning set.
For each of the 3 steps in the “outer level” cross-validation, prognosis predictors (one for each
dataset) were built based on the learning samples using the previously described method:
i) determination of the lowest number of genes and the lowest number of nearest neighbors
giving the lowest number of false predictions (out of 12), using 6-fold cross-validation (“inner
level” of cross-validation); ii) selection of the m informative genes based on the 12 patients.
The prognosis predictors were used to assign a prognosis to the 6 test samples. The predicted
prognoses were then compared to the actual recurrence status, giving a false prediction rate
(out of 6). The 3 false prediction rates (one for each of the 3 steps of the “outer level” crossvalidation) were averaged to provide an estimate of the generalization error.

Software
The statiscal analysis was performed with the open-source software R, Version 2.0.1
(http://cran.r-project/org),

and

Bioconductor

packages

(www.bioconductor.org).

The

following R packages were used : affy Version 1.5.8 (Irizarry RA, Gautier L, Bolstad BM,
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Miller C), annaffy Version 1.0.11 (Smith CA), class Version 7.2.11 (Venables T, Ripley B,
Hornik K, Gebhardt A), hgu133a Version 1.6.5 (Zhang J) and multtest Version 1.5.2 (Pollard
KS, Ge Y, Dudoit S).
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Results

Selection of prognosis predictor parameters
For each dataset (T and NM), a total of 150 prognosis predictors (50 possible values for the
number m of informative genes, 3 possible values for the number k of nearest neighbors) were
considered and their performance assessed using 6-fold cross-validation. The distributions of
the numbers of false predictions obtained with each of these 150 predictors are given in
Figure 1. Results were quite similar for non-neoplastic mucosa and tumor-based predictors:
no pair of parameters (m, k) allowed a perfect concordance between the predicted and the
observed evolutions; the numbers of false predictions ranged between 2 and 4; two false
predictions (out of 18, accuracy = 89%) represented the most frequent result (108 out of 150
predictors, 72%, with NM; 84 out of 150 predictors, 56%, with T). Figure 2 shows the
numbers of false predictions as a function of both parameters m and k. With the NM dataset,
predictors built with 65 or fewer informative genes yielded 3 and 4 false predictions;
predictors built with more than 70 informative genes yielded stable results (2 false
predictions); the lowest number of informative genes giving the lowest number of false
predictions (2 out of 18) was m=70 (with k = 3 neighbors). With the T dataset, predictors built
with 25 or fewer informative genes yielded 3 false predictions, whatever the number of
nearest neighbors; predictors built with more than 30 informative genes yielded 2 false
predictions with k=3 and 5 neighbors, and 3 or 4 false predictions with k=1 neighbor; the
lowest number of informative genes giving the lowest number of false predictions (2 out of
18) was m=30 (with k = 3 neighbors).

Proposition of a prognosis predictor
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Based on the results of the 6-fold cross-validation, two prognosis predictors were
proposed. The first predictor, based on the NM expression profiles of all 18 patients, was built
by selecting the 70 genes with largest absolute t-statistics. Of these genes, 35 were overexpressed in patients who developed a recurrence, while the other 35 were over-expressed in
patients who remained disease-free for at least 5 years. Both lists of genes are given in Table
1. Informative genes can be divided into three categories:
1) plasma membrane receptors (guanine nucleotide binding protein, lysosomalassociated membrane protein, tumor necrosis factor superfamily member 6, prostanglandin
E receptor 2, interleukin 1 receptor, peptide YY, a disintegrin and metalloproteinase domain
28, glucagon) with members of different signaling pathways (serine/threonine kinase 25,
casein kinase 1, tyrosine kinase 2, transducin-like enhancer of split 2, member T2 of ras
homolog gene family, insulin-like growth factor 1, neufibromin 2, integral membrane protein
2A), and transcription factors (erythroid-derived 2-like 1, zinc finger protein 36, v-jun
sarcoma virus 17 oncogene homolog, mitochondrial transcription factor A);
2) proteins involved in cell growth and/or maintenance (CDC2-like 10) such as
carbohydrate or amino acid metabolism (mitochondrial F1 complex of ATP synthase H+
transporting, gamma-glutamyltransferase 1, member A2 of aldehyde dehydrogenase 3 family,
adenosylmethionine

decarboxylase

1,

UDP-N-acetyl-alpha-D-galactosamine),

protein

biosynthesis (transport (sorting nexin 4) and degradation (carboxypetidase A3);
3) proteins involved in the immune response (T cell immune regulator 1, microtubuleassociated protein RP/EB family) .
Similarly, to build the tumor-based predictor, informative genes were selected using all 18
patients, by taking the 30 genes with the largest absolute t-statistics. Of these genes, 16 were
over-expressed in patients who developed a recurrence, while the other 14 were overexpressed in patients who remained disease-free for at least 5 years. Both lists of genes are
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given in Table 2. Genes over-expressed in the tumors of patients who recurred coded for
proteins involved in nucleic acid and protein metabolism (a member of COP9 family, member
Z of H2A histone family, SRB7 suppressor of RNA polymerase B, v-yes-1, stress 70 protein
chaperone, CDC28 protein kinase regulatory subunit 1B, dynactin 3, DnaJ/Hsp40 homolog,
mitochondrial ribosomal protein L24, APG12). Also over-expressed in the tumors of patients
who recurred were genes coding for proteins of the extracellular matrix (e.g., matrix
metalloproteinase 12), and proteins of the immune response (e.g., interleukin 8).

Estimation of the generalization error of the prognosis predictor
The results of the double cross-validation are summarized in Table 3 (Non-neoplastic
mucosa) and Table 4 (Tumor). In both Tables, each row gives the results of one of the 3 steps
of the “outer level” cross-validation. For each step, 12 samples were used as the learning set,
while the other 6 were used as the test set. In both Tables, the first set of columns indicates the
distribution of the numbers of false predictions (out of 12) obtained with each of the 150
predictors in the “inner level” cross-validation based on the 12 patients of the learning set.
The second column gives the lowest numbers of informative genes and nearest neighbors that
yielded the lowest number of false predictions for the “inner level” cross-validation (6-fold
cross-validation). These parameter values were used to build the prognosis predictor based on
the learning set of size 12. This predictor was then applied to assign a prognosis to each of the
6 patients of the test set. The false prediction rates, obtained for each of the 3 steps, are given
in the third column. The average of these 3 false prediction rates provides an estimate of the
generalization error of the predictors. The estimate of the generalization error was 17% for the
70-gene non-neoplastic mucosa-based predictor, and 22% for the 30-gene tumor-based
predictor. Thus, the estimated accuracy of these two predictors was 83% and 78%,
respectively.
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Discussion

The aim of the present study was to build a prognosis predictor that could be used, for
both stage II and stage III colon cancer, to identify patients at high risk of recurrence and thus
more likely to benefit from a more aggressive postoperative treatment. The statistical analysis
was therefore performed on the combined sample of stage II and III patients but did not
include any sub-analyses by stage of disease due to the small sample size. Patients were
homogeneous with regard to the postoperative treatment, as they all received the current
“standard” treatment: none of the 10 stage II patients received any adjuvant chemotherapy,
while all 8 stage III patients received a 6-month FU-based adjuvant chemotherapy. With this
“standard” treatment, 9 patients remained disease-free for at least 5 years and 9 developed a
metastatic recurrence. The latter type of patients is of interest as it represents individuals who
may potentially have benefited from a more aggressive treatment. Note that a pooled analysis
allows us to draw a common conclusion for stage II and III patients, but does not allow any
separate conclusions for either group.

Studies aiming to propose a predictor, for either diagnosis or prognosis purposes, are
usually designed as follows: samples are split into a training set and a validation set;
informative genes and possibly other prediction parameters are selected based on the training
set, using some arbitrary rule; the resulting predictor is assessed on the validation set. The
design of the present study, which includes two distinct rounds of cross-validation with
different aims, deserves further discussion. The first part concerns the selection of a predictor,
while the second aims to estimate the generalization error of the selected predictor. The knearest neighbor classifier was chosen because it has been shown to be competitive with more
complex approaches, such as aggregated classification trees and support vector machines
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(Dudoit et al., 2003; Dudoit and Fridlyand, 2003). The main parameters of this classifier,
namely the numbers of informative genes m and nearest neighbors k, were not chosen a-priori
but using cross-validation in the first part of the study.
For both types of predictors (non-neoplastic mucosa and tumor-based), 150 different
pairs of parameters were considered and the performance of the corresponding predictors was
assessed using 6-fold cross-validation. While this first part mainly aimed to select the
predictor parameters, it also yielded information about the stability of non-neoplastic mucosa
and tumor-based prognosis predictors, i.e., the sensitivity of prediction error to the parameters
(m,k).
Based on results of the first cross-validation, two prognosis predictors (a 30-gene
tumor-based predictor and a 70-gene non-neoplastic mucosa-based predictor) were built on
the whole set of patients. When proposing a predictor, it is important to provide an estimate of
its accuracy. As a second set of independent samples was not available, a double crossvalidation design was used, with an “inner level” 6-fold cross-validation for parameter
selection and an “outer level” 3-fold cross-validation for performance assessment of the
selected predictor. In order to obtain an honnest estimate of generalization error, it is crucial
that all aspects of predictor selection be included in the cross-validation process. Thus, for
each of the 3 steps of the “outer level” cross-validation, we reproduced exactly what had been
done in the first part of the study with an “inner level” cross-validation: i) selection of the
parameters (m, k) yielding the best results by 6-fold cross-validation, ii) use of this
information to build a predictor based on the 12 learning set patients. Note that the estimate of
the generalization error, obtained by averaging the error estimates of the “outer level” crossvalidation, should be conservative, since it is computed based on sets of 12 patients (instead
of 18). This suggests that the accuracy of the proposed predictors is not over-estimated.
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The results of the present study clearly suggest the possibility to build an accurate
prognosis predictor for both stage II and III colon cancer patients based on microarray gene
expression measures. This first conclusion supports the findings of two previous reports, even
though different colon cancer subtypes were considered. The study of Bertucci et al. (Bertucci
et al., 2004), which comprised all stages of disease, identified a gene set that separated
patients with significantly different 5-year survival and suggested the relative closeness of
tumor gene expression profiles in patients with synchronous metastases and in those with
metachronous metastases. The study of Wang et al. (Wang et al., 2004), which focussed on
stage II colon cancer, identified a 23-gene signature that predicted prognosis with 78%
accuracy (the same accuracy as that of our 30-gene tumour-based predictor). Thus, it appears
more and more likely that microarray gene expression profiling will prove to be a valuable
tool to predict the prognosis of colon cancer patients, as previously suggested for other types
of cancer (Bhattacharjee et al., 2001; Beer et al., 2002; Rosenwald et al., 2002; Shipp et al.,
2002; Van de Vijver et al., 2002; Van’t Veer et al., 2002).

The main finding of our study is the possibility to build a prognosis predictor based
on either tumor or non-neoplastic mucosa gene expression profiles. To our knowledge, the
issue of profiling non-neoplastic tissue surrounding the tumour for prognosis purpose has
never been addressed before, neither for colorectal cancer nor for other types of solid
tumours. The idea of studying the non-neoplastic mucosa was suggested by growing evidence
that phenomena in cancer are not confined to tumour cells but also involve adjacent cells
(“microenvironment theory”). There is an increasing evidence that interactions between
stromal and cancer cells are a prerequisite for metastases to occur (Mueller and Fusenig,
2004). However, it remains unclear whether this metastatic potential originates in cancer cells
and/or in stromal compartments. Metastatic potential may be present from the origin of the
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tumour (Bernards and Weinberg, 2002; Ramaswamy et al., 2003). Hence, non-neoplastic
mucosa on which the tumor has arisen may contain some helpful information. This hypothesis
is supported by a recent study in which several genes involved in human colon cancer were
shown to have an altered expression in the morphologically normal colonic mucosa (Chen et
al., 2004).

The question of whether one should build a prognosis predictor based on tumor or
non-neoplastic mucosa gene expression profiles immediately arises. The estimated accuracy
of the 70-gene non-neoplastic mucosa-based predictor was greater than that of the 30-gene
tumor-based predictor (83 versus 78%). However, given the limited sample size, this
difference is not sufficient to conclude to the superiority of the non-neoplastic mucosa. Useful
information can be drawn from the cross-validation selection part of the study regarding the
stability of both predictors, i.e., their sensitivity to changes in parameter values. At first sight,
results observed with both predictors may appear equivalent: the range of false predictions
was the same (2 to 4) and the percentages of predictors yielding 2 or 3 false predictions were
very close (95 and 98% for non-neoplastic mucosa- and tumor-based predictors, respectively).
However, when considering the distribution of the numbers of false predictions as a function
of the numbers of informative genes m and neighbors k, the tumor and non-neoplastic
mucosa predictors exhibit a different behavior. With non-neoplastic mucosa-based predictors,
three and four false predictions were only observed with predictors built with fewer than 65
informative genes; with predictors built with 70 or more informative genes, error rates seemed
to stabilize, i.e., they were not influenced by changes in either the number of genes m or the
number of neighbors k. A similar zone of stability was not observed with tumor-based
predictors. With k=1 nearest neighbor, the numbers of false predictions varied with the
number of informative genes; likewise, for a given number of informative genes, error rates
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were influenced by the number of nearest neighbors. This higher stability of non-neoplastic
mucosa-based predictors represents an argument in favor of their use. Non-neoplastic mucosa
samples are homogeneous while tumor samples include both cancer and stromal cells. Thus, it
is possible that differences in stability between the two types of predictors simply reflect this
difference in tissue homogeneity. In the present study, laser-capture microdissection was not
used. This technique could have possibly yielded more stable results for tumor-based
predictors. However, laser-capture microdissection cannot be considered as a routine
technique, for reasons of cost, time, and technical difficulties. Hence, in addition to their
possibly higher accuracy, NM-based predictors have practical advantages over T-based
predictors.

While our results may not conclusively establish the superiority of NM-based
predictors, they do emphasize the potential usefulness of the non-neoplastic mucosa in
predicting the prognosis of stage II and III colon cancer patients. Such a finding is not really
surprising since there is growing evidence that the tumour microenvironment, largely
orchestrated by inflammatory cells, is involved in the neoplastic process, fostering cell
proliferation, survival, and migration (Mueller and Fusenig, 2004). Genetic or gene
expression changes could occur without altering the DNA sequence and explain how stromal
cells escape the normally growth-inhibitory effects and become willing partners in enhancing
epithelial tumor progression. Accordingly, we have observed in tumors the over-expression of
stromal cell genes previously reported to play a major role in the tumor migration (e.g., matrix
metalloproteinase 12 and interleukin 8). The over-expression of members of these gene
families has been observed in most of the gene expression profile studies of epithelial tumors
associated with a metastatic potential. These genes play a particularly crucial role in
carcinogenesis, since an increased expression in the mammary gland of the extra-cellular
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matrix-degrading enzyme, matrix metalloproteinase-3, has been shown to be sufficient to
induce mammary tumors (Sternlicht et al., 1999). As in previous gene expression studies on
colon tumors, a significant change in the expression of gene families coding for proteins
involved in carbohydrate metabolism, in ATP biosynthesis, in cell cycle and mitosis, and in
protein synthesis such as those coding for ribosomal proteins, has been also observed.
Numerous genes involved in signalling pathways were found to be over-expressed in the nonneoplastic mucosa of patients who remained disease-free and who recurred, suggesting the
possibility of a cross-talk between “normal” cells distant from the tumor and tumoral cells.
Indeed, these genes included some coding for membrane receptors (e.g., tumor necrosis factor
receptor 6 (TNFR6), prostanglandin E receptor 2, interleukin 1 receptor (IL1R)) and others
coding for proteins involved in signalling cascades (most of them involved in the MAPK, JakSTAT, and Wnt signalling pathways). The role of these signalling pathways has been
previously reported in other studies of gene expression in colorectal tumors. Thus, the crosstalk, previously shown between stromal and cancer cells, could be relayed in the nonneoplastic mucosa far from the primary tumor. Similarly, the concept that inflammation is a
crucial component of tumor progression could play a major role from afar the tumor. Indeed,
the over-expression of membrane receptors such as TNFR6, prostanglandin E receptor 2, and
IL1R supports this hypothesis. As also expected, an over-expression of genes coding for
proteins implicated in immune surveillance has been found. Thus, our results favour a view in
which the apparently normal tissue in which a tumor appears and develops may contain or
acquire information on the ability of this tumor to further invade and disseminate. The control
exerted by non-tumoral tissue on neoplastic lesion formation may be part of the homeostatic
tissue functions that may be either genetically “weak” or altered by continuous chemical or
inflammatory aggressions.
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In conclusion, the present study suggests the possibility to build an accurate prognosis
predictor using gene expression profiles for stage II and III colon cancer patients. More
remarkably, it suggests that such a predictor may be based on either the non-neoplastic
mucosa or the tumor gene expression profiles. The study also raises questions regarding the
role of the “normal mucosa” surrounding the tumor.
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Table 1. Differentially expressed genes in non-neoplastic mucosa samples.
Over-expressed genes in patients who developed a recurrence
Affy
Gene Name
Probe ID

GenBank
Accession Number

213415_at
220442_at
207080_s_at
205997_at
204697_s_at
202889_x_at
206121_at
220622_at
209541_at
204674_at
204781_s_at
206631_at
202742_s_at
212652_s_at
204207_s_at
219747_at
211372_s_at
217251_x_at
208284_x_at
201988_s_at
210544_s_at
201196_s_at
210767_at
206422_at
218374_s_at
203176_s_at
219036_at
201805_at
205624_at
202501_at
201768_s_at
208870_x_at

AI768628
NM_003774
NM_004160
NM_021778
NM_001275
T62571
NM_000036
NM_024727
AI972496
NM_006152
NM_000043
NM_000956
NM_002731
AA524345
AB012142
NM_024574
U64094
AF043583
NM_013421
BF438056
BC002430
M21154
BC003112
NM_002054
NM_020374
BE552470
NM_024491
NM_002733
NM_001870
NM_014268
BC004467
BC000931

Chloride intracellular channel 2
UDP-N-acetyl-alpha-D-galactosamine
peptide YY
a disintegrin and metalloproteinase domain 28
chromogranin A (parathyroid secretory protein 1)
microtubule-associated protein 7
adenosine monophosphate deaminase 1 (isoform M)
hypothetical protein FLJ23259
insulin-like growth factor 1 (somatomedin C)
lymphoid-restricted membrane protein
tumor necrosis factor receptor superfamily, member 6
prostaglandin E receptor 2 (subtype EP2), 53kDa
protein kinase, cAMP-dependent, catalytic, beta
sorting nexin 4
RNA guanylyltransferase and 5'-phosphatase
hypothetical protein FLJ23191
interleukin 1 receptor, type II

gamma-glutamyltransferase 1
cAMP responsive element binding protein-like 2
aldehyde dehydrogenase 3 family, member A2
adenosylmethionine decarboxylase 1
neurofibromin 2 (bilateral acoustic neuroma)
glucagon
chromosome 12 open reading frame 4
transcription factor A, mitochondrial
p10-binding protein
protein kinase, AMP-activated, gamma 1 non-catalytic subunit
carboxypeptidase A3 (mast cell)
microtubule-associated protein, RP/EB family, member 2
enthoprotin
ATP synthase, H+ transporting, mitochondrial F1 complex,
gamma polypeptide 1
202746_at
integral membrane protein 2A
210951_x_at RAB27A, member RAS oncogene family
209515_s_at RAB27A, member RAS oncogene family

AL021786
AF125393
U38654

Over-expressed genes in patients who remained disease-free
Affy
Gene Name
Probe ID

GenBank
Accession Number

212212_s_at
33132_at
214494_s_at
201464_x_at
201314_at
212796_s_at
211996_s_at
217223_s_at
221899_at

BF055496
U37012
NM_005200
BG491844
NM_006374
BF195608
BG256504
U07000
AI809961

DKFZP586J0619 protein
cleavage and polyadenylation specific factor 1, 160kDa
v-jun sarcoma virus 17 oncogene homolog (avian)
serine/threonine kinase 25 (STE20 homolog, yeast)
KIAA1055 protein
split hand/foot malformation (ectrodactyly) type 3 pseudogene 1
phosphonoformate immuno-associated protein 5
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201480_s_at
220762_s_at
219053_s_at
202573_at
201553_s_at
222210_at
217931_at
200759_x_at
205546_s_at
200799_at
203317_at
210622_x_at
222219_s_at
212280_x_at
203469_s_at
204158_s_at
221214_s_at
205583_s_at
222131_x_at
211962_s_at
207743_at
203624_at
201466_s_at
215235_at
221800_s_at
37028_at

suppressor of Ty 5 homolog (S. cerevisiae)
guanine nucleotide binding protein (G protein), beta polypeptide
1-like
hypothetical protein FLJ20847
casein kinase 1, gamma 2
lysosomal-associated membrane protein 1
CASK interacting protein 2
trinucleotide repeat containing 5
nuclear factor (erythroid-derived 2)-like 1
tyrosine kinase 2
heat shock 70kDa protein 1A
pleckstrin and Sec7 domain containing 4
cyclin-dependent kinase (CDC2-like) 10
transducin-like enhancer of split 2 (E(sp1) homolog, Drosophila)
APG4 autophagy 4 homolog B (S. cerevisiae)
cyclin-dependent kinase (CDC2-like) 10
T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal
V0 protein a isoform 3
nasal embryonic LHRH factor
hypothetical protein FLJ23018
ras homolog gene family, member T2
zinc finger protein 36, C3H type-like 1
PRO1880 protein
DNA segment on chromosome X and Y (unique) 155 expressed
sequence
v-jun sarcoma virus 17 oncogene homolog (avian)
spectrin, alpha, non-erythrocytic 1 (alpha-fodrin)
hypothetical protein FLJ22175
protein phosphatase 1, regulatory (inhibitor) subunit 15A

NM_003169
NM_022446
NM_017966
AL530441
NM_005561
AK025262
BC004423
NM_003204
NM_003331
NM_005345
NM_012455
AF153430
AC007766
AA532726
NM_003674
NM_006019
NM_015537
NM_024810
BC004327
BG250310
NM_014104
NM_005088
NM_002228
AL110273
AA551370
U83981
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Table 2. Differentially expressed genes in tumor samples.
Over-expressed genes in patients who developed a recurrence
Affy
Gene Name
Probe ID
204580_at
matrix metalloproteinase 12 (macrophage elastase)
208737_at
ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G
isoform 1
218042_at
COP9 constitutive photomorphogenic homolog subunit 4
(Arabidopsis)
200853_at
H2A histone family, member Z
211506_s_at interleukin 8
209362_at
SRB7 suppressor of RNA polymerase B homolog (yeast)
210754_s_at v-yes-1 Yamaguchi sarcoma viral related oncogene homolog
202558_s_at stress 70 protein chaperone, microsome-associated, 60kDa
200096_s_at ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e
201897_s_at CDC28 protein kinase regulatory subunit 1B
204246_s_at dynactin 3 (p22)
202842_s_at DnaJ (Hsp40) homolog, subfamily B, member 9
218919_at
hypothetical protein FLJ14007
218270_at
mitochondrial ribosomal protein L24
213026_at
APG12 autophagy 12-like (S. cerevisiae)
210907_s_at programmed cell death 10
Over-expressed genes in patients who remained disease-free
Affy
Gene Name
Probe ID
215364_s_at KIAA0467 protein
204535_s_at RE1-silencing transcription factor
209446_s_at hypothetical protein FLJ10803
222252_x_at chromosome 1 open reading frame 6
213155_at
KIAA0523 protein
217586_x_at
202032_s_at mannosidase, alpha, class 2A, member 2
219516_at
transient receptor potential cation channel, subfamily V,
member 4
220505_at
chromosome 9 open reading frame 53
209848_s_at silver homolog (mouse)
205451_at
myeloid/lymphoid or mixed-lineage leukemia (trithorax
homolog, Drosophila), translocated to, 7
203995_at
chromosome 21 open reading frame 2
207499_x_at
207863_at
ADP-ribosylarginine hydrolase

GenBank
Accession Number
NM_002426
BC003564
NM_016129
NM_002106
AF043337
AI688580
M79321
NM_006948
AI862255
NM_001826
NM_007234
AL080081
NM_024699
NM_024540
BE965998
BC002506
GenBank
Accession Number
AB007936
AI978576
BC001743
AK023354
AB011095
N35922
NM_006122
NM_021625
NM_016349
U01874
NM_005938
NM_004928
NM_017979
NM_001125
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Table 3. Results of the double cross-validation. Non-neoplastic mucosa.
Step in
outer level
3-fold CV
Step 1
Step 2
Step 3

Inner level 6-fold CV,
number of predictors with
1 FP * 2 FP * 3 FP * 4 FP *
129
18
3
57
91
2
12
85
53

Parameters selected
in inner level CV
(m,k)
m = 40 , k = 1
m = 15 , k = 3
m = 70 , k = 5

FP Rate on outer
level CV test set
1/6
1/6
1/6
17% **

FP: False prediction
CV: Cross-validation
*: Out of 12 samples, for inner level 6-fold cross-validation
**: Generalization error, out of 18 samples, for outer level 3-fold cross-validation
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Table 4. Results of the double cross-validation. Tumor.
Step in
outer level
3-fold CV
Step 1
Step 2
Step 3

0 FP *
65

Inner level 6-fold CV,
number of predictors with
1 FP * 2 FP * 3 FP * 4 FP *
3
146
1
77
8
106
44

Parameters
selected in inner
level CV (m,k)
m = 10 , k = 1
m=5,k=1
m = 35 , k = 1

FP Rate on
outer level
CV test set
2/6
1/6
1/6
22% **

FP: False prediction
CV: Cross-validation
* : out of 12 samples, for inner level 6-fold cross-validation
**: generalization error, out of 18 samples, for outer level 3-fold cross-validation

27
Hosted by The Berkeley Electronic Press

Figure 1. Distributions of the numbers of false predictions.

For each dataset (non-neoplastic mucosa and tumor datasets), a total of 150 prognosis
predictors - 50 possible values for the number m of informative genes (m = 5, 10, …, 250), 3
possible values for the number k of nearest neighbors (k = 1, 3, and 5) - were considered and
their performance assessed using 6-fold cross-validation. Figure 1 shows the distribution of
the numbers of false predictions (out of 18) obtained with each of these 150 predictors.

28
http://biostats.bepress.com/ucbbiostat/paper178

Figure 2. Number of false predictions.

Figure 2 shows, for each dataset (non-neoplastic mucosa and tumor datasets), the numbers of
false predictions as a function of the number m of informative genes (x-axis) and the number
k of nearest neighbors (y-axis). In these pseudo-color images, colored rectangles indicate the
number of false predictions, with yellow (red) corresponding to the lowest (highest) numbers
of errors.
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